Takeshi Yuasa

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 38

Top Topics

Metastatic Renal Cell Carcinoma

Editorial Comment

Prognostic Factors

Top Venues

IJU case reports

International journal of urology : official journal of the Japanese Urological Association

Cancer reports (Hoboken, N.J.)

This page only lists publications with an associated author ORCID identifier.

Publications

Takeshi Yuasa
Editorial comment to Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy. International journal of urology : official journal of the Japanese Urological Association (2024)
Ryo Fujiwara, Shinya Yamamoto, Kosuke Takemura, Takeshi Yuasa, Noboru Numao, Tomohiko Oguchi, Yosuke Yasuda, Yusuke Yoneoka, Junji Yonese
Clinical Outcomes and Prognostic Factors in Nonmetastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors Therapy. Cancers 16 (15) (2024)
Takeshi Yuasa
Editorial comment to Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy. International journal of urology : official journal of the Japanese Urological Association 31 (5) (2024)
Takeshi Yuasa
Editorial comment to Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy. International journal of urology : official journal of the Japanese Urological Association 31 (5) (2024)
Takeshi Yuasa
Editorial comment to Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy. International journal of urology : official journal of the Japanese Urological Association 31 (5) (2024)
Ryo Fujiwara, Shinya Yamamoto, Kosuke Takemura, Takeshi Yuasa, Noboru Numao, Tomohiko Oguchi, Yosuke Yasuda, Yusuke Yoneoka, Junji Yonese
Clinical Outcomes and Prognostic Factors in Nonmetastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors Therapy. Cancers 16 (15) (2024)
Takeshi Yuasa
Editorial comment to Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy. International journal of urology : official journal of the Japanese Urological Association 31 (5) (2024)
Takeshi Yuasa
Editorial Comment on Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study. International journal of urology : official journal of the Japanese Urological Association (2023)
Ichiro Yonese, Noboru Numao, Kentaro Inamura, Yusuke Yoneoka, Ryo Fujiwara, Yosuke Yasuda, Tomohiko Oguchi, Shinya Yamamoto, Takeshi Yuasa, Junji Yonese
A case of neoadjuvant chemotherapy-resistant muscle-invasive bladder cancer that markedly responded to pembrolizumab before conversion radical cystectomy. IJU case reports 7 (1) (2023)
Takeshi Yuasa
Editorial Comment to Bone-modifying agents are protective for symptomatic skeletal events in radium-223 treatment. International journal of urology : official journal of the Japanese Urological Association (2023)
Ichiro Yonese, Noboru Numao, Kentaro Inamura, Yusuke Yoneoka, Ryo Fujiwara, Yosuke Yasuda, Tomohiko Oguchi, Shinya Yamamoto, Takeshi Yuasa, Junji Yonese
A case of neoadjuvant chemotherapy-resistant muscle-invasive bladder cancer that markedly responded to pembrolizumab before conversion radical cystectomy. IJU case reports 7 (1) (2023)
Minami Une, Ryo Fujiwara, Arisa Ueki, Ryosuke Oki, Tetsuya Urasaki, Kentaro Inamura, Shunji Takahashi, Junji Yonese, Takeshi Yuasa
A case of sequential medical therapy for advanced ureteral cancer in Li-Fraumeni syndrome. IJU case reports 6 (5) (2023)
Takeshi Yuasa
Editorial Comment to Plasma circulating tumor DNA profiling in patients with chemo-refractory germ cell tumors. International journal of urology : official journal of the Japanese Urological Association (2023)
Minami Une, Ryo Fujiwara, Arisa Ueki, Ryosuke Oki, Tetsuya Urasaki, Kentaro Inamura, Shunji Takahashi, Junji Yonese, Takeshi Yuasa
A case of sequential medical therapy for advanced ureteral cancer in Li-Fraumeni syndrome. IJU case reports 6 (5) (2023)
Yosuke Yasuda, Masato Sakurai, Noboru Numao, Shinya Yamamoto, Junji Yonese, Takeshi Yuasa
Efficacy and safety profile of olaparib for patients with metastatic castration-resistant prostate cancer: A preliminary report of real-world data in a single institution in Japan. International journal of urology : official journal of the Japanese Urological Association (2023)
Ryosuke Oki, Tetsuya Urasaki, Arisa Ueki, Kentaro Inamura, Yoshinobu Komai, Shunji Takahashi, Junji Yonese, Takeshi Yuasa
A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome. IJU case reports 6 (1) (2022)
Kosuke Hamada, Ryo Fujiwara, Kosuke Takemura, Yoshinobu Komai, Tomohiko Oguchi, Noboru Numao, Shinya Yamamoto, Junji Yonese, Takeshi Yuasa
Tumor shrinkage patterns of nivolumab monotherapy in metastatic renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association 29 (10) (2022)
Takeshi Yuasa
Editorial Comment from Dr Yuasa to Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association 29 (7) (2022)
Takeshi Yuasa
Editorial Comment to A case of steroid-resistant cystitis as an immune-related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab. IJU case reports 5 (6) (2022)
Takeshi Yuasa
Editorial Comment to Clinicopathological features of adrenal malignancies: Analysis of hospital-based cancer registry data in Japan. International journal of urology : official journal of the Japanese Urological Association 29 (11) (2022)
Eri Fukagawa, Takeshi Yuasa, Kentaro Inamura, Kosuke Hamada, Motohiro Fujiwara, Yoshinobu Komai, Junji Yonese
De novo large-cell neuroendocrine carcinoma of the prostate: A case report and literature review. IJU case reports 5 (6) (2022)
Takeshi Yuasa
Editorial Comment to Interstitial lung disease induced by apalutamide therapy for castration-resistant prostate cancer: A report of a rare case. IJU case reports 5 (3) (2022)
Takeshi Yuasa
Editorial Comment to Cystic partially differentiated nephroblastoma in a 74-year-old patient. IJU case reports 4 (6) (2021)
Tetsuya Urasaki, Masatoshi Nishizawa, Atsushi Yoshida, Junichi Tomomatsu, Takeshi Yuasa, Junji Yonese, Shunji Takahashi
Severe pseudomembranous keratoconjunctivitis with deterioration of eyesight induced by immune checkpoint inhibitors. Immunotherapy (2021)
Takeshi Yuasa
Editorial Comment to Expression of tertiary lymphoid structure in deferred cytoreductive nephrectomy of metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. IJU case reports 4 (6) (2021)
Shotaro Yasuoka, Takeshi Yuasa, Motohiro Fujiwara, Junko Fujisaki, Kentaro Inamura, Yoshinobu Komai, Noboru Numao, Shinya Yamamoto, Junji Yonese
Unusual metastasis from renal cell cancer after partial nephrectomy and sequential targeted therapy. IJU case reports 4 (3) (2021)
Motohiro Fujiwara, Takeshi Yuasa, Tetsuya Urasaki, Yoshinobu Komai, Ryo Fujiwara, Noboru Numao, Shinya Yamamoto, Junji Yonese
Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single-center analysis in Japan. Cancer reports (Hoboken, N.J.) (2021)
Takeshi Yuasa
Editorial Comment to Testicular metastasis from urothelial carcinoma of the bladder. IJU case reports 5 (2) (2021)
Kasumi Kaneko Yoshitomi, Noboru Numao, Yosuke Umino, Motohiro Fujiwara, Ryo Fujiwara, Tomohiko Oguchi, Yoshinobu Komai, Takeshi Yuasa, Shinya Yamamoto, Junji Yonese
The utility of diffusion-weighted whole-body imaging with background body signal suppression in detecting metastatic lesion of germ cell carcinoma. IJU case reports 4 (5) (2021)
Takeshi Yuasa
Editorial Comment to A case of adenocarcinoma of the rete testis with durable response to cisplatin-based chemotherapy. IJU case reports 4 (5) (2021)
Motohiro Fujiwara, Hajime Tanaka, Takeshi Yuasa, Yoshinobu Komai, Tomohiko Oguchi, Ryo Fujiwara, Noboru Numao, Shinya Yamamoto, Yasuhisa Fujii, Iwao Fukui, Junji Yonese
First-line combination chemotherapy with etoposide, ifosfamide and cisplatin for the treatment of disseminated germ cell cancer: Efficacy and feasibility in current clinical practice. International journal of urology : official journal of the Japanese Urological Association 28 (9) (2021)
Takeshi Yuasa
Editorial comment from Dr Yuasa to Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma. IJU case reports 3 (6) (2020)
Takeshi Yuasa
Editorial Comment from Dr Yuasa to Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma. IJU case reports 3 (5) (2020)
Yuta Sano, Motohiro Fujiwara, Takeshi Yuasa, Yoshinobu Komai, Tatsuya Yamamoto, Atsushi Kohno, Masayuki Nakao, Kentaro Inamura, Junji Yonese
Testicular seminoma with a progressing pulmonary nodule and mediastinal lymphadenopathy without retroperitoneal metastasis. IJU case reports 3 (5) (2020)
Motohiro Fujiwara, Yoshinobu Komai, Takeshi Yuasa, Noboru Numao, Shinya Yamamoto, Iwao Fukui, Junji Yonese
Pembrolizumab for a patient with metastatic castration-resistant prostate cancer with microsatellite instability-high. IJU case reports 3 (2) (2020)
Takeshi Yuasa
Editorial Comment to Syndrome of inappropriate antidiuretic hormone secretion as a side effect of chemotherapy for testicular cancer: A case report. IJU case reports 2 (6) (2019)
Takeshi Yuasa
Editorial Comment to Possible abscopal effect in urothelial carcinoma of the upper urinary tract after treatment with immune checkpoint inhibitors. IJU case reports 3 (1) (2019)
Takeshi Yuasa, Shinji Urakami, Junji Yonese
Recent advances in medical therapy for metastatic urothelial cancer. International journal of clinical oncology 23 (4) (2018)